|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
PL4023249T3
(pl)
|
2014-04-23 |
2025-03-10 |
Modernatx, Inc. |
Szczepionki z kwasem nukleinowym
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
MA42502A
(fr)
|
2015-07-21 |
2018-05-30 |
Modernatx Inc |
Vaccins contre une maladie infectieuse
|
|
MA42543A
(fr)
|
2015-07-30 |
2018-06-06 |
Modernatx Inc |
Arn épitope peptidiques concatémériques
|
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
AU2016342045A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
AU2016342376A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Sexually transmitted disease vaccines
|
|
AU2016341309A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Cancer vaccines
|
|
EP4011451A1
(en)
|
2015-10-22 |
2022-06-15 |
ModernaTX, Inc. |
Metapneumovirus mrna vaccines
|
|
WO2017070601A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
WO2017070624A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Tropical disease vaccines
|
|
PL3386484T3
(pl)
|
2015-12-10 |
2022-07-25 |
Modernatx, Inc. |
Kompozycje i sposoby dostarczania środków terapeutycznych
|
|
US10465190B1
(en)
|
2015-12-23 |
2019-11-05 |
Modernatx, Inc. |
In vitro transcription methods and constructs
|
|
NZ746112A
(en)
|
2016-03-18 |
2023-01-27 |
Immune Sensor Llc |
Cyclic di-nucleotide compounds and methods of use
|
|
EP3445392A1
(en)
*
|
2016-04-22 |
2019-02-27 |
CureVac AG |
Rna encoding a tumor antigen
|
|
IL263079B2
(en)
|
2016-05-18 |
2024-05-01 |
Modernatx Inc |
Polynucleotides encoding relaxin
|
|
WO2017201342A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding jagged1 for the treatment of alagille syndrome
|
|
CA3036831A1
(en)
|
2016-09-14 |
2018-03-22 |
Modernatx, Inc. |
High purity rna compositions and methods for preparation thereof
|
|
EP3528821A4
(en)
|
2016-10-21 |
2020-07-01 |
ModernaTX, Inc. |
HUMAN CYTOMEGALOVIRUS VACCINE
|
|
MA46766A
(fr)
|
2016-11-11 |
2019-09-18 |
Modernatx Inc |
Vaccin antigrippal
|
|
WO2018107088A2
(en)
|
2016-12-08 |
2018-06-14 |
Modernatx, Inc. |
Respiratory virus nucleic acid vaccines
|
|
US11384352B2
(en)
|
2016-12-13 |
2022-07-12 |
Modernatx, Inc. |
RNA affinity purification
|
|
AU2018219862B2
(en)
*
|
2017-02-07 |
2020-09-17 |
Nant Holding IP, LLC |
Maximizing T-cell memory and compositions and methods therefor
|
|
MA47515A
(fr)
|
2017-02-16 |
2019-12-25 |
Modernatx Inc |
Compositions immunogènes très puissantes
|
|
WO2018170256A1
(en)
*
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
EP3595713A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
RESPIRATORY SYNCYTIAL VIRUS Vaccine
|
|
EP3595676A4
(en)
|
2017-03-17 |
2021-05-05 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZOONOSES
|
|
US11905525B2
(en)
|
2017-04-05 |
2024-02-20 |
Modernatx, Inc. |
Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
MA49421A
(fr)
|
2017-06-15 |
2020-04-22 |
Modernatx Inc |
Formulations d'arn
|
|
MA49914A
(fr)
|
2017-08-18 |
2021-04-21 |
Modernatx Inc |
Procédés analytiques par hplc
|
|
WO2019036682A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
RNA VARIANTS POLYMERASE
|
|
EP3668979A4
(en)
|
2017-08-18 |
2021-06-02 |
Modernatx, Inc. |
METHOD OF HPLC ANALYSIS
|
|
EP3675817A1
(en)
|
2017-08-31 |
2020-07-08 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
WO2019055807A1
(en)
|
2017-09-14 |
2019-03-21 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZIKA VIRUS
|
|
EP3746090A4
(en)
|
2018-01-29 |
2021-11-17 |
ModernaTX, Inc. |
RSV RNA Vaccines
|
|
WO2019227106A1
(en)
*
|
2018-05-25 |
2019-11-28 |
The Wistar Institute |
Tumor-specific neoantigens and methods of using the same
|
|
AU2019293244B2
(en)
*
|
2018-06-27 |
2026-04-02 |
Modernatx, Inc. |
Personalized cancer vaccine epitope selection
|
|
US20220349010A1
(en)
|
2018-07-26 |
2022-11-03 |
Frame Pharmaceuticals B.V. |
Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
|
|
CA3106564A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Cancer vaccines for breast cancer
|
|
CA3113025A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Peg lipids and uses thereof
|
|
WO2020061295A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
BR112021006941A2
(pt)
|
2018-10-19 |
2021-08-31 |
The Francis Crick Institute Limited |
Antígenos de câncer inovadores e métodos
|
|
MA54192A
(fr)
*
|
2018-11-07 |
2021-09-15 |
Modernatx Inc |
Vaccins à arn contre le cancer
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
AU2020208193A1
(en)
*
|
2019-01-14 |
2021-07-29 |
BioNTech SE |
Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
US11851694B1
(en)
|
2019-02-20 |
2023-12-26 |
Modernatx, Inc. |
High fidelity in vitro transcription
|
|
AU2020224103A1
(en)
|
2019-02-20 |
2021-09-16 |
Modernatx, Inc. |
Rna polymerase variants for co-transcriptional capping
|
|
CN113874502A
(zh)
|
2019-03-11 |
2021-12-31 |
摩登纳特斯有限公司 |
补料分批体外转录方法
|
|
US20220184191A1
(en)
*
|
2019-03-11 |
2022-06-16 |
Evaxion Biotech A/S |
Nucleic acid vaccination using neo-epitope encoding constructs
|
|
US12070495B2
(en)
|
2019-03-15 |
2024-08-27 |
Modernatx, Inc. |
HIV RNA vaccines
|
|
WO2020198338A1
(en)
*
|
2019-03-25 |
2020-10-01 |
Ohio State Innovation Foundation |
Combination immunoregulation and uses thereof
|
|
EP3962521A1
(en)
|
2019-05-02 |
2022-03-09 |
University of Florida Research Foundation, Inc. |
Compositions for treatment of diffuse intrinsic pontine glioma
|
|
US20220236253A1
(en)
*
|
2019-05-31 |
2022-07-28 |
Modernatx, Inc. |
Expanded t cell assay
|
|
US12577278B2
(en)
*
|
2019-06-07 |
2026-03-17 |
Emory University |
KRAS G12V mutant binds to JAK1, inhibitors, pharmaceutical compositions, and methods related thereto
|
|
CN110172089B
(zh)
*
|
2019-06-11 |
2020-01-07 |
北京鼎成肽源生物技术有限公司 |
一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
|
|
CN110172480B
(zh)
*
|
2019-06-11 |
2020-01-07 |
北京鼎成肽源生物技术有限公司 |
双抗原表位融合基因重组慢病毒载体、抗原提呈细胞和ctl细胞及其构建方法和应用
|
|
US20220307017A1
(en)
*
|
2019-08-29 |
2022-09-29 |
Universität Zürich |
Minimal Messenger RNAs and uses thereof
|
|
CR20220220A
(es)
|
2019-11-18 |
2022-09-20 |
Janssen Biotech Inc |
Vacunas basadas en calr y jak2 mutantes y sus usos
|
|
WO2021119418A1
(en)
*
|
2019-12-11 |
2021-06-17 |
Vanderbilt University |
Methods of synthesizing mrna and functional proteins from synthetic double stranded dna
|
|
EP4096720A2
(en)
*
|
2020-01-30 |
2022-12-07 |
ModernaTX, Inc. |
Mrnas encoding metabolic reprogramming polypeptides and uses thereof
|
|
MX2022009391A
(es)
*
|
2020-01-31 |
2022-09-26 |
Genentech Inc |
Metodos para inducir linfocitos t especificos para neoepitopo con un antagonista de union al eje de pd-1 y una vacuna de arn.
|
|
US20230096704A1
(en)
*
|
2020-02-05 |
2023-03-30 |
University Of Florida Research Foundation, Incorporated |
Rna-loaded nanoparticles and use thereof for the treatment of cancer
|
|
IL296234A
(en)
*
|
2020-03-11 |
2022-11-01 |
Advansix Resins & Chemicals Llc |
Surfactants for healthcare products
|
|
JP2023517664A
(ja)
|
2020-03-11 |
2023-04-26 |
アドバンシックス・レジンズ・アンド・ケミカルズ・リミテッド・ライアビリティ・カンパニー |
油及びガス生産のための界面活性剤
|
|
JP2023517666A
(ja)
|
2020-03-11 |
2023-04-26 |
アドバンシックス・レジンズ・アンド・ケミカルズ・リミテッド・ライアビリティ・カンパニー |
農業用製品のための界面活性剤
|
|
JP2023522193A
(ja)
*
|
2020-04-17 |
2023-05-29 |
ザ フランシス クリック インスティチュート リミティッド |
抗原プール
|
|
IL297419B2
(en)
|
2020-04-22 |
2025-02-01 |
BioNTech SE |
Coronavirus vaccine
|
|
US11130787B2
(en)
*
|
2020-06-11 |
2021-09-28 |
MBF Therapeutics, Inc. |
Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods
|
|
KR20230034333A
(ko)
|
2020-07-02 |
2023-03-09 |
라이프 테크놀로지스 코포레이션 |
트리뉴클레오티드 캡 유사체, 제조 및 이의 용도
|
|
EP4175664A2
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
US20230346924A1
(en)
*
|
2020-08-04 |
2023-11-02 |
Progeneer Inc. |
Mrna vaccine comprising adjuvant capable of kinetic control
|
|
IL300447A
(en)
|
2020-08-12 |
2023-04-01 |
Actym Therapeutics Inc |
Bacteria-based ingredients that stimulate the immune system, treatments and platforms for delivering RNA
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
CA3198727A1
(en)
|
2020-10-20 |
2022-04-28 |
St Pharm Co., Ltd. |
Oligonucleotide for 5'-capped rna synthesis
|
|
WO2022087424A1
(en)
*
|
2020-10-22 |
2022-04-28 |
The Regents Of The University Of California |
Monoamine oxidase blockade therapy for treating cancer through regulating tumor associated macrophages (tams)
|
|
WO2022120560A1
(zh)
*
|
2020-12-08 |
2022-06-16 |
深圳市瑞吉生物科技有限公司 |
一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用
|
|
US20240299516A1
(en)
*
|
2020-12-21 |
2024-09-12 |
University Of Florida Research Foundaton, Inc. |
Multilamellar rna nanoparticle vaccine against cancer
|
|
CN114717229B
(zh)
*
|
2021-01-05 |
2024-09-10 |
麦塞拿治疗(香港)有限公司 |
治疗性mRNA的无细胞和无载体体外RNA转录方法和核酸分子
|
|
EP4274607A1
(en)
|
2021-01-11 |
2023-11-15 |
ModernaTX, Inc. |
Seasonal rna influenza virus vaccines
|
|
US20240299520A1
(en)
*
|
2021-02-09 |
2024-09-12 |
Virginia Commonwealth University |
Mini circular rna therapeutics and vaccines and methods of use thereof
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
EP4313072A1
(en)
*
|
2021-03-26 |
2024-02-07 |
ModernaTX, Inc. |
Pertussis vaccine
|
|
NL2028681B1
(en)
*
|
2021-04-02 |
2022-10-17 |
Nutcracker Therapeutics Inc |
Materials and methods for generating antigen-specific t cells and treating diseases
|
|
CN113186285B
(zh)
*
|
2021-05-10 |
2022-05-24 |
深圳市展行生物有限公司 |
一种辅助诊断胃癌的方法及其使用的miRNA组合
|
|
US20220363937A1
(en)
|
2021-05-14 |
2022-11-17 |
Armstrong World Industries, Inc. |
Stabilization of antimicrobial coatings
|
|
CN113577258B
(zh)
*
|
2021-07-31 |
2024-04-16 |
山东兴瑞生物科技有限公司 |
一种双靶点mRNA疫苗及其制备方法
|
|
CN115703714B
(zh)
*
|
2021-08-13 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
WO2023030635A1
(en)
*
|
2021-09-02 |
2023-03-09 |
BioNTech SE |
Potency assay for therapeutic potential of coding nucleic acid
|
|
CA3230564A1
(en)
|
2021-09-13 |
2023-03-16 |
Jean-Pol DETIFFE |
Method to generate personalized neoantigens of a tumor of a patient
|
|
EP4147713A1
(en)
*
|
2021-09-13 |
2023-03-15 |
OncoDNA |
A rna vaccine comprising an rna pool generated from a double-stranded dna pool
|
|
EP4147712A1
(en)
|
2021-09-13 |
2023-03-15 |
OncoDNA |
Method to generate a double-stranded dna pool encoding neoantigens of a tumor of a patient
|
|
WO2023086796A2
(en)
|
2021-11-09 |
2023-05-19 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
|
|
US12186387B2
(en)
|
2021-11-29 |
2025-01-07 |
BioNTech SE |
Coronavirus vaccine
|
|
US12529047B1
(en)
|
2021-12-21 |
2026-01-20 |
Modernatx, Inc. |
mRNA quantification methods
|
|
CN116376942A
(zh)
*
|
2021-12-31 |
2023-07-04 |
广州国家实验室 |
mRNA疫苗
|
|
WO2024002985A1
(en)
|
2022-06-26 |
2024-01-04 |
BioNTech SE |
Coronavirus vaccine
|
|
WO2024026490A1
(en)
*
|
2022-07-28 |
2024-02-01 |
Sqz Biotechnologies Company |
Polynucleotides encoding linked antigens and uses thereof
|
|
CN115992152A
(zh)
*
|
2022-09-22 |
2023-04-21 |
浙江大学医学院附属第一医院 |
一种用于乙型肝炎病毒治疗性mRNA疫苗及其制备方法与应用
|
|
CN120019151A
(zh)
*
|
2022-10-07 |
2025-05-16 |
国立大学法人筑波大学 |
核酸构建物及蛋白复合体的设计方法及制造方法
|
|
EP4604981A2
(en)
*
|
2022-10-19 |
2025-08-27 |
KaliVir Immunotherapeutics, Inc. |
Nucleic acids encoding soluble pd-1 and il-12 and uses thereof
|
|
EP4611918A1
(en)
*
|
2022-10-31 |
2025-09-10 |
Gritstone bio, Inc. |
Combination panel cell-free dna monitoring
|
|
WO2024097874A1
(en)
*
|
2022-11-03 |
2024-05-10 |
Modernatx, Inc. |
Chemical stability of mrna
|
|
EP4364752A1
(en)
|
2022-11-07 |
2024-05-08 |
OncoDNA |
Improved vaccine
|
|
CN116970614A
(zh)
*
|
2022-12-29 |
2023-10-31 |
达冕疫苗(广州)有限公司 |
编码ny-eso-1的核糖核酸疫苗的组合物和方法
|
|
US20240238408A1
(en)
*
|
2023-01-17 |
2024-07-18 |
The University Of Hong Kong |
CANCER IMMUNOTHERAPY BY DELIVERY OF mRNA
|
|
CN119055669A
(zh)
*
|
2023-05-23 |
2024-12-03 |
源生生物科技(青岛)有限责任公司 |
包含miRNA的活性成分及其应用
|
|
WO2025054383A1
(en)
*
|
2023-09-06 |
2025-03-13 |
Modernatx, Inc. |
Chemical stability of mrna
|
|
WO2025080869A1
(en)
*
|
2023-10-11 |
2025-04-17 |
The Regents Of The University Of California |
Pancreatic cancer immunotherapy using cationic lipid and polymer nanocarriers for co-delivery of kras neoantigens and sting and/or other immunomodulators to boost the cancer immunity cycle and treat liver metastasis
|
|
WO2025117816A1
(en)
*
|
2023-12-01 |
2025-06-05 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
CN121464216A
(zh)
*
|
2024-01-17 |
2026-02-03 |
艾博生物科技(上海)有限公司 |
用于诱导针对kras突变细胞的抗原特异性免疫的组合物和方法
|
|
WO2025158069A1
(en)
*
|
2024-01-25 |
2025-07-31 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
CONSTRUCT COMPRISING mRNA-STRAND AND RETINOIC ACID-INDUCIBLE GENE I (RIG-I)-LIGAND(S), PHARMACEUTICAL COMPOSITION AND KIT COMPRISING THE SAME
|
|
CN118389553A
(zh)
*
|
2024-03-01 |
2024-07-26 |
中国科学技术大学 |
免疫增效rna分子及其组合物、疫苗与试剂盒
|
|
CN117883558B
(zh)
*
|
2024-03-15 |
2024-06-14 |
山东兴瑞生物科技有限公司 |
靶向肝肿瘤个性化mRNA疫苗的制备方法
|
|
WO2025235990A1
(en)
*
|
2024-05-10 |
2025-11-13 |
Metrohealth Ventures Llc |
Cancer oncogene mrna vaccine
|
|
WO2026005647A2
(ru)
*
|
2024-06-29 |
2026-01-02 |
федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации |
Иммунобиологическое средство для терапии онкологических заболеваний на основе мрнк вектора
|
|
CN119874872B
(zh)
*
|
2025-01-17 |
2025-11-25 |
武汉大学 |
一种mita铰链区突变多肽及其在自身免疫性疾病中的应用
|